Selinexor and Pembrolizumab for the Treatment of Cisplatin-Ineligible or Cisplatin-Refractory Locally Advanced or Metastatic Urothelial Carcinoma
University of California, Davis
University of California, Davis
Incyte Corporation
NuCana plc
Case Comprehensive Cancer Center
University of Washington
Inhibrx Biosciences, Inc
Sumitomo Pharma America, Inc.
University of Florida
Mirati Therapeutics Inc.
Advaxis, Inc.
University of Utah
Incyte Corporation
Rainier Therapeutics